§ 01 Overview
Overview
Non-peptide oral GLP-1 agonist in late Phase III trials, offering daily pill dosing without the restrictions of oral semaglutide.
Phase III ACHIEVE program read out in 2024–2025 with strong efficacy signals.
§ 02 Mechanism
Mechanism of action
Orforglipron binds the GLP-1 receptor as a non-peptide small molecule. Unlike oral semaglutide, it does not require a protective absorption enhancer or fasted administration.
- 01Convenient oral daily dosing
- 02Weight loss comparable to injectable GLP-1s in Phase II
- 03Potential for broader access given oral form
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 7 – 45 mg daily
- Starting Dose
- 3 mg daily
- Route
- Oral
- Timing
- Any time
- Frequency
- Daily
- Cycle
- Titrate every 4 weeks.
§ 04 Evidence
Evidence & research
Phase III ACHIEVE program read out in 2024–2025 with strong efficacy signals.
FDA Status
Investigational. Filed with FDA in 2025.
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison - Pharmafile
Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison Pharmafile
Orforglipron’s MACE Data Just Raised the Evidentiary Bar for Every Oral GLP-1 Program Behind It - The Clinical Trial Vanguard
Orforglipron’s MACE Data Just Raised the Evidentiary Bar for Every Oral GLP-1 Program Behind It The Clinical Trial Vanguard
What to Know About the GLP-1 Pill Orforglipron - Medscape
What to Know About the GLP-1 Pill Orforglipron Medscape
EASD: Daily Orforglipron Pill Shows Comparable Cardiovascular Safety to Insulin Glargine - HealthDay
EASD: Daily Orforglipron Pill Shows Comparable Cardiovascular Safety to Insulin Glargine HealthDay
Weight loss with Orforglipron: Does menopausal stage matter? - Medical News Today
Weight loss with Orforglipron: Does menopausal stage matter? Medical News Today
Efficacy and Safety of Oral Orforglipron for Weight Reduction in Adults With Overweight or Obesity: A Systematic Review - The Cureus Journal of Medical Science
Efficacy and Safety of Oral Orforglipron for Weight Reduction in Adults With Overweight or Obesity: A Systematic Review The Cureus Journal of Medical Science
Foundayo: Oral GLP-1 Demonstrated Up to 14% Weight Loss for All Women - Healthline
Foundayo: Oral GLP-1 Demonstrated Up to 14% Weight Loss for All Women Healthline
Orforglipron Shows Greater A1C, Weight Reduction Than Oral Semaglutide - Drug Topics
Orforglipron Shows Greater A1C, Weight Reduction Than Oral Semaglutide Drug Topics
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Nausea
- 02Diarrhea
- 03Constipation
Contraindications
None specified.
§ 10 Questions
Oral GLP Compound (ER-ORF) FAQ
- What is Oral GLP Compound (ER-ORF)?
- Non-peptide oral GLP-1 agonist in late Phase III trials, offering daily pill dosing without the restrictions of oral semaglutide. Orforglipron binds the GLP-1 receptor as a non-peptide small molecule. Unlike oral semaglutide, it does not require a protective absorption enhancer or fasted administration.
- What is Oral GLP Compound (ER-ORF) used for?
- Reported uses include convenient oral daily dosing, weight loss comparable to injectable glp-1s in phase ii, and potential for broader access given oral form. Evidence strength is rated Clinical — see the evidence section for detail.
- How is Oral GLP Compound (ER-ORF) dosed?
- Commonly referenced dosing is 7 – 45 mg daily, administered Oral. This is educational reference only; consult a licensed clinician before use.
- What are the side effects of Oral GLP Compound (ER-ORF)?
- Commonly reported side effects include nausea, diarrhea, and constipation. This list is not exhaustive.
- Is Oral GLP Compound (ER-ORF) legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Investigational. Filed with FDA in 2025..